In medicinal chemistry, one of the most studied molecules in recent history is taxol. Taxol is a versatile natural product that is used in various cancer treatment regimens. It is administered to patients with breast, lung, and ovarian cancers, and is currently being studied for the treatment of squamous cell carcinoma of the oral cavity and tongue. Taxol has been tested in a number of research and clinical phase trials to determine feasibility, toxicity, and cytotoxicity against oral squamous cell carcinoma as a single drug regimen and as a contributing drug component in treatment plans. This paper reviews over forty articles that examine cell lines, murine models, and human results for the response of taxol against squamous cell carcinoma (SCC) of the oral cavity and the tongue.

No abstract

While the development of chemotherapeutic agents has lead to progress in the treatment of small-cell carcinomas of the lung, the number of local recurrences still remains high. Surgery in tumors stage I and II followed by postoperative chemotherapy is the treatment of choice and has been accepted worldwide. In tumors stage IIIa, especially in T1-3 N2 we obtained good results in the projected 3-year survival using a multimodality therapeutic regime consisting of neoadjuvant chemotherapy (3 cycles preoperative) and surgery as well as postoperative chemotherapy and irradiation of the mediastinum. Projected 3-year survival was 67% in stage I tumors, 42% in stage II and with our multimodality therapeutic regime 38% in stage III a tumors.

No abstract